Virological Failure & Second-Line ART Pathway

NACO Treatment Failure Assessment & Regimen Switch · v1.8
← HIV Clinical Hub
How to use this tool: Enter the current regimen, the viral load history and the adherence assessment. The tool returns a second-line regimen. Virological failure means a viral load above 1000 copies/mL on two consecutive measurements three months apart, after at least six months on ART, with adherence support documented.
1. Failed First-Line Regimen
2. Failure Confirmation
3. Adherence Assessment
4. Current Parameters
Types of Treatment Failure
TypeDefinitionPreferred Metric
VirologicalVL > 1000 copies/mL on 2 consecutive samples 3 months apart, after ≥ 6 months on ARTGold standard. Primary trigger for switch.
ImmunologicalCD4 falls to (or below) pre-ART level, or persistent CD4 < 100 after 6 months, or 50% fall from peakLess reliable. May lag 6 to 12 months behind VL failure.
ClinicalNew or recurrent WHO Stage 4 event after 6 months on ARTLeast reliable. Must exclude IRIS. Only use if VL is unavailable.
1. Adherence Assessment Before Switch
NACO mandates adherence counselling before any regimen switch. A confirmed unsuppressed VL with poor adherence should trigger intensive adherence support for 3 months, followed by a repeat VL. Only if VL remains > 1000 despite good adherence should the switch occur. Premature switching in the setting of poor adherence risks wasting the second-line regimen.
2. Second-Line Drug Pearls
ATV/r (Atazanavir/Ritonavir 300/100mg OD): Preferred PI. Causes unconjugated hyperbilirubinaemia (scleral icterus) in up to 40%, cosmetically distressing but clinically benign. Avoid with PPIs (drastically reduces ATV absorption). Take with food.
LPV/r (Lopinavir/Ritonavir 200/50mg, 2 tabs BD): Alternative PI. GI side effects (diarrhoea, nausea) are common and may limit adherence. Heat-stable tablets preferred over syrup. Significant metabolic effects (dyslipidaemia, insulin resistance).
Third-Line ART: Available only at designated ART Plus centres. Regimen: DRV/r 600/100mg BD + optimised backbone + RAL 400mg BD or DTG 50mg BD. Requires specialist review and often genotypic resistance testing.
Abbreviations: ABC (Abacavir) · ART (Antiretroviral Therapy) · ARV (Antiretroviral) · ATV (Atazanavir) · ATV/r (Atazanavir/Ritonavir) · AZT (Zidovudine) · BD (Twice Daily) · CD4 (Cluster of Differentiation 4) · CrCl (Creatinine Clearance) · DRV/r (Darunavir/Ritonavir) · DTG (Dolutegravir) · ECG (Electrocardiogram) · EFV (Efavirenz) · FDC (Fixed-Dose Combination) · GI (Gastrointestinal) · H2 blocker (Histamine H2 Receptor Antagonist) · Hb (Haemoglobin) · HBV (Hepatitis B Virus) · HCV (Hepatitis C Virus) · HIV (Human Immunodeficiency Virus) · IAC (Intensive Adherence Counselling) · INSTI (Integrase Strand Transfer Inhibitor) · IRIS (Immune Reconstitution Inflammatory Syndrome) · LDL (Low-Density Lipoprotein) · LFT (Liver Function Test) · LPV/r (Lopinavir/Ritonavir) · NACO (National AIDS Control Organisation) · NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor) · NRTI (Nucleoside Reverse Transcriptase Inhibitor) · NVP (Nevirapine) · OD (Once Daily) · PI (Protease Inhibitor) · PPI (Proton Pump Inhibitor) · RAL (Raltegravir) · SBAR (Situation, Background, Assessment, Recommendation) · TAF (Tenofovir Alafenamide) · TDF (Tenofovir Disoproxil Fumarate) · TLd (Tenofovir + Lamivudine + Dolutegravir) · TLE (Tenofovir + Lamivudine + Efavirenz) · VL (Viral Load) · WHO (World Health Organization) · 3TC (Lamivudine)
References
  1. NACO. National Guidelines for HIV Care and Treatment. MoHFW, GoI; 2021.
  2. NACO. National Technical Guidelines on ART. 2018 (Updated 2021).
  3. WHO. Consolidated guidelines on HIV. 2021.
  4. World Health Organization. WHO updated recommendations on HIV clinical management: recommendations for a public health approach. Geneva: WHO; 7 January 2026. [First substantial revision since 2021. DRV/r becomes the preferred boosted PI; supports reuse of TDF and ABC in subsequent regimens; long-acting injectable ART and oral two-drug regimens in defined circumstances; revised vertical transmission and TB preventive treatment guidance. NACO remains the operative source for Indian practice.]
How to Cite

AMA: Umakanth S. Virological Failure & Second-Line ART Pathway. MEDiscuss. 2026. Accessed .

Vancouver: Umakanth S. Virological Failure & Second-Line ART Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

Disclaimer and scope
Disclaimer: This decision-support system is intended for healthcare professionals. It does not substitute clinical judgment. These algorithms are evidence-based, but medical knowledge evolves continuously. The treating physician retains absolute responsibility for all diagnostic, dosing, and therapeutic decisions. Always verify outputs against current institutional protocols and individual patient contexts.
© 2026 MEDiscuss.org. All rights reserved. This CDSS Module was designed and developed by Dr. Shashikiran Umakanth using the available evidence base. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Therapeutic & Management PathwaysPathway
Specialties Internal Medicine, Infectious Diseases, HIV Medicine
Written and maintained by Dr Shashikiran Umakanth.
Last revised: 8 August 2026
Related Clinical Tools
First-Line ART SelectionART Monitoring & ADR GuideHIV Clinical Pathway Hub
Back to All Medical Calculators & Pathways